Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma

Oncology

Volumn 82, Issue 1, 2012, Pages 11-18

  Lee, Danbi ^a   Chung, Young Hwa ^a   Kim, Jeong A ^a   Lee, Yoon Seon ^a   Lee, Don ^a   Jang, Myoung Kuk ^b   Kim, Kang Mo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Hepatocellular carcinoma; Invasiveness; Transforming growth factor beta 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862798754     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000335605     Document Type: Article

References (30)

1. Raoul JL: Natural history of hepatocellular carcinoma and current treatment options. Semin Nucl Med 2008; 38:S13-18.
2. Park NH, Song IH, Chung YH: Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J 2006; 82: 507-515. (Pubitemid 44258625)
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. (Pubitemid 46890874)
4. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358. (Pubitemid 30408720)
5. Derynck R, Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1997; 1333:F105-F150.
6. Yang EY, Moses HL: Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111: 731-741.
7. Okumoto K, Hattori E, Tamura K.Kiso S, Watanabe H, Saito K, Saito T, Togashi H, Kawata S: Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004; 24: 21-28. (Pubitemid 38351210)
8. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-3920. (Pubitemid 16122096)
9. Ito N, Kawata S, Tamura S,Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Nishioka M, Tarui S: Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991; 51: 4080-4083.
10. Street RL Jr, Voigt B, Geyer C Jr, Manning T, Swanson GP: Increasing patient involvement in choosing treatment for early breast cancer. Cancer 1995; 76: 2275-2285.
11. Bedossa P, Peltier E, Terris B, Franco D, Poynard T: Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995; 21: 760-766.
12. Song BC, Chung YH, Kim JA,Song IH, Koh MS, Lee HC, Yu E, Lee YS, Suh DJ: Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-180. (Pubitemid 34049056)
13. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds): American Joint Committee on Cancer Staging Manual, ed 6. New York, 2002.
14. Bissell DM, Roulot D, George J: Transforming growth factor beta and the liver. Hepatology 2001; 34: 859-867. (Pubitemid 33032019)
15. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S: Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005; 129: 1375-1383. (Pubitemid 41597379)
16. Katabami K, Mizuno H, Sano R, Saito Y, Ogura M, Itoh S, Tsuji T: Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factorbinding motif in the promoter region. Clin Exp Metastasis 2005; 22: 539-548. (Pubitemid 43234638)
17. Lu Y, Wu LQ, Li CS, Wang SG, Han B: Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int 2008; 7: 174-178. (Pubitemid 351524062)
18. Teicher BA: Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 2001; 20: 133-143. (Pubitemid 34074689)
19. Yao DF, Dong ZZ, Yao M: Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007; 6: 241-247. (Pubitemid 46925243)
20. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S: Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002; 161: 183-193. (Pubitemid 34760784)
21. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127:S35-S50. (Pubitemid 39423368)
22. Lok AS: Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004; 127:S303-S309. (Pubitemid 39423400)
23. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360. (Pubitemid 39331462)
24. Shimizu Y, Minemura M, Tsukishiro T, Kashii Y, Miyamoto M, Nishimori H, Higuchi K, Watanabe A: Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 1995; 22: 525-531.
25. Song BC, Chung YH, Kim JA, Lee HC, Yoon HK, Sung KB, Yang SH, Yoo K, Lee YS, Suh DJ: Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: A prospective study. Cancer 2001; 91: 2386-2393. (Pubitemid 32552826)
26. Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 159-167. (Pubitemid 43157409)
27. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK, Tang ZY, Qin LX: The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132: 709-717. (Pubitemid 44337931)
28. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K: Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17: 607-614. (Pubitemid 29075249)
29. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y: Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994; 73: 2275-2279. (Pubitemid 24129108)
30. Flisiak R, Pytel-Krolczuk B, Prokopowicz D: Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-681. (Pubitemid 30453497)